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Background: Invasion of tumor cells into adjacent brain parenchyma is a major cause of treatment failure in
glioblastoma. Furthermore, invasive tumors are shown to have a different genomic composition and metabolic
abnormalities that allow for a more aggressive GBM phenotype and resistance to therapy. We thus seek to identify
those genomic abnormalities associated with a highly aggressive and invasive GBM imaging-phenotype.
Methods: We retrospectively identified 104 treatment-naïve glioblastoma patients from The Cancer Genome Atlas
(TCGA) whom had gene expression profiles and corresponding MR imaging available in The Cancer Imaging Archive
(TCIA). The standardized VASARI feature-set criteria were used for the qualitative visual assessments of invasion. Patients
were assigned to classes based on the presence (Class A) or absence (Class B) of statistically significant invasion
parameters to create an invasive imaging signature; imaging genomic analysis was subsequently performed using
GenePattern Comparative Marker Selection module (Broad Institute).
Results: Our results show that patients with a combination of deep white matter tracts and ependymal invasion (Class A)
on imaging had a significant decrease in overall survival as compared to patients with absence of such invasive
imaging features (Class B) (8.7 versus 18.6 months, p < 0.001). Mitochondrial dysfunction was the top canonical
pathway associated with Class A gene expression signature. The MYC oncogene was predicted to be the top
activation regulator in Class A.
Conclusion: We demonstrate that MRI biomarker signatures can identify distinct GBM phenotypes associated with
highly significant survival differences and specific molecular pathways. This study identifies mitochondrial dysfunction
as the top canonical pathway in a very aggressive GBM phenotype. Thus, imaging-genomic analyses may prove
invaluable in detecting novel targetable genomic pathways.
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Recent advances in high throughput whole-genome glio-
blastoma (GBM) analyses have led to an increase in the
understanding of gliomagenesis and elucidation of new
molecular pathways [1,2]. However, the dismal prognosis
of GBM remains largely unchanged with the median sur-
vival less than 2 years [3]. Heterogeneity in cellular com-
position, differential genomic expression profiles and
therapy-resistant cancer stem cells within a single tumor
(intra-tumor heterogeneity) and with the “same” tumor
across different individuals (inter-individual heterogen-
eity) contribute largely to the lack of advancement in
therapeutic approaches for these heterogeneous tumors
and lie central to the failure of significant progress in
the treatment of GBM [4,5]. Cellular invasion remains a
significant cause of therapy failure as diffuse dissemin-
ation of tumor cells throughout the entire GBM brain
including the normal appearing white matter precludes
clean surgical margins. Moreover, glioma stem-like
cells, thought to be involved in invasion, do not respond
to current chemotherapeutic agents which target the ac-
tive tumor core [6,7].
Magnetic resonance imaging (MRI) has been shown to
non-invasively reflect the underlying tumor biological
and pathological processes [7,8], tumor microenviron-
ment [9], and genomic cancer composition [10-13]. Mul-
tiple preoperative imaging characteristics consistent with
invasive tumor growth are documented [13,14]. Qualita-
tively, these include the 1) presence of either T1 contrast
enhancement or increase T2/FLAIR hyperintensity invol-
ving the internal capsule, corpus callosum (unilateral, bi-
lateral, or contralateral) or brainstem; 2) the presence of
ependymal enhancement; and 3) the presence of pial en-
hancement [14]. Quantitatively, 3D volumetry of the peri-
tumoral non-enhancing FLAIR hyperintensity has been
validated to reflect an increase in gene signatures promo-
ting cellular invasion and angiogenesis, as shown by our
group previously [13]. In this current study, we sought to
identify the invasive MRI characteristics in GBM and the
implicated genes and microRNAs associated with qualita-
tive invasive imaging signatures. Using our large-scale
genomic database provided by The Cancer Genome Atlas
(TCGA) and the imaging of the corresponding TCGA pa-
tients provided by The Cancer Imaging Archive (TCIA),
we performed an MRI radiophenotype screen to identify
key genes and molecular pathways associated with a very
aggressive GBM radiophenotype.Methods
The collection of the original material and data of
TCGA and TCIA study was conducted in compliance
with all applicable laws, regulations and policies for the
protection of human subjects, and any necessary approvals,authorizations, human subject assurances, informed con-
sent documents, and IRB approvals were obtained [2].
Patient population and TCGA and TCIA
We identified 104 (female 38: male 66; mean age
58 years; age range from 14 to 84 years) treatment-naïve
GBM patients from TCGA whom had gene expression
profiles and corresponding pretreatment MR imaging
available in the TCIA. The TCGA is a National Cancer
Institute (NCI) sponsored publicly available resource
which has produced a multi-dimensional genomic and
clinical data set of GBM and other cancers [2]. Image
data used in this research were obtained from TCIA
(http://cancerimagingarchive.net/) sponsored by the Can-
cer Imaging Program, DCTD/NCI/NIH [15]. The latter
archive repository contains the imaging corresponding to
the patients of the TCGA.
Image acquisition and analysis
All images were downloaded from the NCI’s TCIA
(http://cancerimagingarchive.net/) [15]. Image analysis
was performed as previously published by our group
[13,16]. Standard imaging parameters were used for each
of the sequences as noted in the TCIA database [15].
Image analysis
For each patient, three board-certified neuroradiologists
independently reviewed pre- and post- contrast axial
T1-weighted MR images as well as axial T2-weighted
FLAIR images. Images were analyzed using the Clear-
canvas platform (ClearCanvas, Toronto, Canada; http://
www.clearcanvas.ca/) and each physician entered speci-
fied imaging findings in an installed electronic case re-
port form that implemented the VASARI feature set for
human GBM [16-19]. Each board-certified neuroradiolo-
gist (C.H., 15 years of experience; A.F., 22 years; S.H., 5
years; M.W., 6 years; P.R., 4 years; R.R.C., 3 years; and
M.J., 3 years) recorded a set of mark-ups for 30 imaging
features describing the size, location, and morphology of
the tumor.
Included in the standardized VASARI feature-set cri-
teria are qualitative visual assessments for key features
of invasion: 1) deep white matter tract (DWMT) in-
volvement [presence of either T1 contrast enhancement
or increase T2/FLAIR hyperintensity involving the in-
ternal capsule, corpus callosum (unilateral, bilateral, or
contralateral), or brainstem]; 2) the presence of ependymal
enhancement; and 3) the presence of pial enhancement
(Figure 1). Other parameters also analyzed were enhan-
cing tumor crossing the midline, non-enhancing tumor
crossing the midline, tumor extension into cortex, defi-
nition of the enhancing margin, definition of the non-
enhancing tumor margin, proportion of edema, presence
and absence of cysts and hemorrhage.
Figure 1 Image example of qualitative invasive phenotype: ependymal extension. 33 year old female patient with right frontal GBM.
(a) Axial and (b) coronal post-contrast T1-weighted images demonstrate extension of enhancing tumor into the ependymal region of the frontal
horn of the right lateral ventricle. (c) Axial FLAIR image demonstrates non-enhancing tumor as well to extend to the ependymal region.
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Proportional hazards regression was performed with
each of the following qualitative invasive covariates as a
predictor of survival, taken individually: 1) DWMT in-
volvement: presence of either T1 contrast enhancement
or increase T2/FLAIR hyperintensity involving the in-
ternal capsule, corpus callosum (unilateral, bilateral, or
contralateral), or brainstem; 2) ependymal enhancement;
and 3) pial invasion. Proportional hazards regression was
similarly performed on other imaging parameters as
follows: enhancing tumor crossing the midline, non-
enhancing tumor crossing the midline, tumor extension
into cortex, definition of the enhancing margin, defin-
ition of the non-enhancing tumor margin, proportion of
edema, presence and absence of cysts and hemorrhage.
Bonferroni correction was performed. Kaplan-Meier meth-
od (log-rank test) was used to compute overall median
survival. Data table preparation was done in Microsoft
Excel 2010 and then loaded into the JMP Pro 9.01 (SAS
Institute, Cary NC) and R-project (Bioconductor platform)
software packages for statistical analysis.
Patients were subsequently classified based on pres-
ence or absence of the invasion MRI phenotypes that
were statistically significant. Class A patients demon-
strated the presence of all the independent statistically
significant parameters of invasion. Patients who had no in-
vasion phenotypes or presence of only one were assigned
to Class B.
Biostatistical image- genomic analysis
Affymetrix level 1 mRNA and Agilent level 1 microRNA
data were downloaded from the public TCGA data por-
tal (April 2013) (http://cancergenome.nih.gov/). Level 1
mRNA Affymetrix CEL file analysis was performed in R
project, a free statistical computing platform, (http://www.
r-project.org/) using the Bioconductor platform (http://
www.bioconductor.org/). Robust Multi-Array (RMA) al-
gorithm was used for normalization [20].In each patient, a total of 13,628 genes (22,267
hybridization probes) were analyzed for significance and
differential fold regulation in Class A versus Class B groups
by Comparative Marker Selection (CMS) (Broad Institute,
MIT, Cambridge, MA, http://www.broadinstitute.org/
cancer/software/genepattern/). CMS is a statistical method
that uses permutation testing to identify differentially regu-
lated genomic events in one versus another predefined pa-
tient group [21].
The top 100 most positively and the top 100 most
negatively correlated mRNAs in the Class A group ver-
sus the Class B group were then analyzed with Ingenuity
Pathway Analysis (IPA) (www.ingenuity.com). IPA pro-
vides insight into the molecular and chemical inter-
actions, cellular phenotypes, and disease processes of a
predefined set of genes and microRNAs. By means of
IPA, our top molecular targets for the Class A group
were analyzed in a comprehensive way and thus pertinent
canonical pathways and functional networks accounting
for an invasion radiophenotype were uncovered. Upstream
transcriptional factor analysis was done using IPA.
Results
Univariate proportional hazards regression model fit for
11 potential predictors of survival
Univariate proportional hazards regression models with
each of the 11 predictors of survival was performed. Of
these 11 invasive imaging predictors, 3 imaging biomarkers
were statistically significant. [Unadjusted p-values: Epen-
dymal (EP) involvement, P = 0.005; deep white matter
tract (DWMT) involvement {presence of either T1 con-
trast enhancement or increase T2/FLAIR hyperintensity
involving the internal capsule, corpus callosum (unilateral,
bilateral, or contralateral), or brainstem}, P = 0.002; en-
hancement across the midline, P = 0.0003]. Bonferroni
adjustment was then performed. [Adjusted p-values:
Ependymal (EP) involvement, P = 0.058; Hazard Ratio
(HR) =1.812, Concordance = 0.593, 95% CI (1.19-2.77);
Figure 3 Kaplan Meier survival curve: enhancing tumor across
midline/corpus callosum. Kaplan Meier method was used to
compute overall median survival. Those who had enhancement
across the midline versus those patients with absence of
enhancement across the midline demonstrated a median overall
survival of 9 months versus 14.3 months (p < 0.0003).
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of either T1 contrast enhancement or increase T2/FLAIR
hyperintensity involving the internal capsule, corpus
callosum (unilateral, bilateral, or contralateral) or brain-
stem}, p = 0.027; HR =1.926, Concordance = 0.6, 95% CI
(1.25-2.96); enhancement across the midline, P = 0.003;
Concordance = 0.546, HR =3.48, 95% CI (1.70-7.15)]. We
fit a final proportional hazards regression model including
these three predictors together. All of the regression coef-
ficients were statistically significant [P = 0.033, HR =
1.616, 95% CI (1.0-2.5); P = 0.015, HR = 1.738, 95% CI
(1.1-2.7); and P = 0.038, HR = 2.219, 95% CI (1.0-4.7), for
ependymal involvement, deep white matter tract involve-
ment and enhancement across the midline, respectively].
This analysis was performed using the 'survival' library
[22] in the R statistics package (http://www.R-project.org).
Invasive imaging phenotypes
Deep white matter tract (DWMT) involvement: En-
hancement across the midline and presence of either T1
contrast enhancement or increase T2/FLAIR hyperinten-
sity involving the internal capsule, corpus callosum (uni-
lateral, bilateral, or contralateral), or brainstem
Forty percent (42/104) of patients had involvement of
the internal capsule, corpus callosum (unilateral, bilateral,
or contralateral), or brainstem either by T1 contrast en-
hancement or increase T2/FLAIR hyperintensity. Sixty
percent (62/104) of patients had no involvement of these
structures. Twenty-six percent (9/35) demonstrated en-
hancement across the midline (across the corpus callo-
sum). Ninety-one percent (95/104) of patients did not
demonstrate enhancing tumor across the midline/corpus
callosum.
Those who had involvement of the DWMT demon-
strated a median overall survival of 10.9 months (95% CI:Figure 2 Kaplan Meier survival curve: Deep white matter tract
[DWMT] involvement. Kaplan Meier method was used to compute
overall median survival. Those who had involvement versus no
involvement of the DWMT demonstrated a median overall survival
of 10.9 months versus 19.9 months (p < 0.0008).7.5-13.3 months) versus 19.9 months (95% CI: 14.1-
24.9 months) (p < 0.0008) (Figure 2). Of those who had
enhancement across the midline, there was a statistically
significant difference in overall survival [5.9 (95% CI: 0.7-
13.3 months) versus 14.3 months (95% CI: 11.9-
18.6 months) (p < 0.0003)] in those patients with presence
versus absence of enhancement across the corpus callo-
sum (Figure 3).Ependymal (EP) enhancement
Forty- three percent (45/104) of patient did not demon-
strate extension of enhancing or non-enhancing tumor to
the ependymal region. Fifty-seven percent (59/104) of pa-
tients had ependymal involvement by tumor. InvolvementFigure 4 Kaplan Meier survival curve: Ependymal [EP]
involvement. Kaplan Meier method was used to compute overall
median survival. Those who had ependymal tumor involvement versus
no ependymal tumor involvement demonstrated an overall survival of
10.6 versus 18.6 months (p = 0.0018).
Figure 5 Kaplan Meier survival curve: Class A versus Class B.
Kaplan Meier method was used to compute overall median survival.
Those patients in Class A (invasive phenotypes) versus those patients in
Class B (without invasive features or only one invasive feature)
demonstrated an overall survival of 8.7 versus 18.6 months (p<0.001).
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overall survival of 10.6 (95% CI: 7.8-13.3 months) versus
18.6 (95% CI: 14.2-22.6 months) months (p = 0.0018)
(Figure 4).
Invasion classes and genomic signatures
A total of 92 patients had comprehensive clinical and
genomic annotation for creation of imaging genomic
signatures. Given that the DWMT and EP imaging radio-
phenotypes were significantly prognostic (p = 0.015 and
p = 0.033) in the proportional hazards model, we used
these two invasion parameters to develop our invasion im-
aging classes. The imaging parameter of tumor across theFigure 6 Canonical pathways associated with Class A patients. Canon
pathway was mitochondrial dysfunction in Class A patients with invasive pmidline was disregarded for further analysis since it only
contained 9 patients that were also present in the DWMT
and EP groups. Patients with both ependymal and deep
white matter tract involvement tumor spread were then
grouped into a single class (Class A; invasive phenotype
group) and those without involvement or involvement of
only one of those parameters were assigned to a second
class (Class B). The patients with involvement of both var-
iables demonstrated a statistically significant worse prog-
nosis (8.9 months) than either variable alone (EP alone =
20 months; DWMT alone = 18.9 months) or no infiltra-
tion at all (18.6 months) which demonstrated similar
prognosis. Forty percent (36/92) of patients were catego-
rized into Class A and 60% (56/92) of patients into Class
B. Class A demonstrated a decrease in survival when com-
pared to Class B [8.9 (95% CI: 6.6-11.2 months) versus
19.6 (95% CI: 14.2-22.6 months) months, p < 0.001)]
(Figure 5). A proportional hazard ratio demonstrated that
the classification was a stronger predictor of survival
(p = 0.0003) than tumor size (p = 0.35) and patient age
(p = 0.93) (data not shown). The top canonical pathway
associated with Class A (invasive phenotype group) was
mitochondrial dysfunction (p = 2.59E-08) (Figures 6, 7
and 8). Transcription Factor Analysis (Figure 9) demon-
strated MYC oncogene activation and inhibition of NF-KB
inhibitor-alpha (NFKBIA) in class A.
Discussion
In this study, we demonstrate that those patients with
specific invasive imaging signatures have a highly signifi-
cant decrease in overall survival and an associated dis-
tinctive genomic expression signature. MR imaging hasical pathway analysis was performed using IPA. The top canonical
henotypes.
Figure 7 The molecules associated with the mitochondrial dysfunctional canonical pathway. In the fold change column, highly up-regulated
genes (red color) and a single down-regulated gene (green color) were presented.
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with underlying genomic events in GBM [12,13,16]. Spe-
cifically, the ependymal involvement, deep white matter
tract involvement and enhancement across the midline
were statistically significant in predicting overall survival;
and MYC oncogene activation and inhibition of NF-KB
inhibitor-alpha (NFKBIA) were seen in class A. These
findings are concordant with those published in the litera-
ture [14]. Furthermore, the location of tumor invasion was
more important than the size of the tumor in predicting
survival (p = 0.0003 versus p = 0.35).Figure 8 Mitochondrial pathway demonstrating location of dysfunctio
with red color and down-regulated gene was labeled with green color.The invasive imaging biomarker signature classes,
Class A (invasive phenotype) and Class B, demonstrated
a significant 9.9 months (8.7 versus 18.6 months, p < 0.0001,
Figure 5) survival disadvantage in Class A. Class A pa-
tients reflected tumor compositions which have genes
involved in invasion and oxidative stress/mitochondrial
biology. In patients in Class A, the top canonical path-
way was mitochondrial dysfunction (Figures 6 and 7).
Furthermore, our classification screen demonstrated
activation of MYC by upstream regulator analysis. The
results of mitochondrial dysfunction and upstreamnal molecules along its spectrum. Up-regulated genes were labeled
Figure 9 Transcriptional factor analysis. Transcriptional factor analysis was performed using IPA to predict the potential transcription factors
involved and their activation or inhibition states in Class A versus Class B groups. MYC and PPARA were predicted to be activated and NFKB1A
was predicted to be inhibited.
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the finding that MYC can activate the transcription of
target genes that increase mitochondrial biogenesis
[23,24]. The findings of altered metabolism in our GBM
patients is concordant with the literature [25,26]. Our
patients with an invasive imaging signature demonstrated
worse survival and altered metabolism. Altered metabol-
ism is one of the important hallmarks of tumor cells
[27,28]. Most cancer cells rely on aerobic glycolysis, a
phenomenon termed “the Warburg effect” [29], the most
well-known metabolic abnormality in cancer cells. This
is unlike that of normal cells which rely on mitochon-
drial oxidative phosphorylation to generate the energy
needed for cellular processes. In the Warburg effect [29],
cancer cells have defects in the mitochondria processes
and there is an increased glycolysis with lactate secretion
and mitochondrial respiration even in the presence of
oxygen [30]. This was also seen in our Class A patients
(Figures 6, 7 and 8). Furthermore, many of the metabolism
genes whose mutations can cause cancers are mitochon-
drial genes [31-33]. Energy metabolism associated genes
IDH1 and IDH2 mutations are seen in secondary GBM
[34,35]. The P53 tumor suppressor and MYC oncogeneFigure 10 Link between NFKBIA and EGFR pathway in Glioblastoma.
using IPA Path Designer tool. Solid line indicates direct biological relationsh
relationship between molecules were supported by IPA knowledge base. Eare well-documented master regulators of metabolism
[36]. The activation of MYC facilitates the Warburg effect
(aerobic glycolysis) and induces glycolysis and glutamino-
lysis, two typical metabolism alterations present in cancer
cells [37]. It has been well known that MYC target genes
are involved in the maintenance of stem cell self-renewal
ability and tumorigenesis [38,39]. Furthermore, aberrant
activation of MYC expression in cancers provide sufficient
energy and anabolic substrates for uncontrolled cell
growth and proliferation in the context of the tumor
microenvironment [36]. Thus, MYC-mediated altered
cancer cell energy metabolism can be a potential target
for the development of new anticancer therapies. Thus,
the literature supports our findings which demonstrated
activation of MYC in those patients with a high invasion
phenotype (Class A).
In our study, we found that NFKBIA was predicted to
be the top inhibited transcriptional factor in Class A by
transcription factor analysis. Nuclear factor of k-light poly-
peptide gene enhancer in B-cells (NF-kB) is a transcription
factor that is activated by the epidermal growth factor
receptor (EGFR) pathway [40] and shows aberrant con-
stitutive activation in GBM [41,42]. NFKBIA repressesThe relationship between EGFR and NF-kB signaling was performed
ip. Dashed line indicates indirect biological relationship. The
GF signaling to NF-kB is affected by NFKBIA inhibition.
Colen et al. BMC Medical Genomics 2014, 7:30 Page 8 of 9
http://www.biomedcentral.com/1755-8794/7/30the NF-kB and thus signaling from the EGFR and NF-kB
pathways [43]. The finding of NFKBIA inhibition in this
study suggests an interesting link between NF-kB path-
way and EGFR signaling in GBM (Figure 10). Mutations
in NFKBIA have been described in multiple cancers in-
cluding GBM cell lines suggesting its function as a
tumor suppressor [44]. Thus, its predicted inhibition is
associated with increased oncogenicity and resistance to
therapy, primarily mediated by its anti-apoptotic activity
[41,45]. This data supports our genomic transcription
factor signature identified by MRI; those patients in
Class A demonstrated a poor survival when compared to
Class B (8.7 versus 18.6 months, p < 0.0001) and had in-
hibition of the NFKBIA transcription factor. NF-kB in-
hibitors have been shown to induce cell death in GBM
[46] and support the possibility of NF-kB as a potential
target for cell death induction for GBM therapy. The de-
velopment of therapeutics targeted against the NF-kB
pathway can possibly address the chemo-resistance seen
in GBM therapy today.
In summary, our study demonstrates for the first time
imaging features that uncover and predict metabolic and
mitochondrial dysfunction in GBM. The effect of the
tumor microenvironment on cancer and the Warburg
effect is increasingly being recognized as important
modulators in genetics and epigenetics as well as facilita-
tors of cancer development [2]. It is now believed that a
better understanding of the mechanisms of the Warburg
effect and altered metabolism may ultimately lead to
more effective treatments for GBM and cancer, in ge-
neral. This study shows that the proposed classification
based on invasive GBM imaging biomarker signatures
yields significant differences in survival and distinct ge-
nomic signatures that identify mitochondrial dysfunction
as a possible driver for very aggressive GBM phenotypes
and resistance to therapy. Certain limitations exist and
are currently being addressed in new prospective clinical
trials and novel animal model experiments. The known
inherent limitation of the TCGA data is that surgical
samples obtained for genomic analysis were not done
using image-guidance and thus the location of biopsy is
unknown. Given tumor heterogeneity in GBM, tissue
sampling under image-guidance is needed to obtain
more accurate specimens. Currently, we are performing
a prospective image-guided biopsy study at our institu-
tion. Further, in-vitro and in-vivo testing in animal
models is also being done in our lab for subsequent va-
lidation of our findings and to identify potential thera-
peutic targets for GBM treatment.
Conclusion
Patients with specific invasive imaging signatures of
ependymal involvement, deep white matter tract involve-
ment and tumor extension across the midline have ahighly significant decrease in overall survival and an asso-
ciated distinctive genomic expression signature. MYC
oncogene activation and inhibition of NFKBIA was seen in
class A. This is a significant finding as these pathways can
have a possible role as a target of therapeutic intervention.
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